Review paper
Inhibition of RANKL as a treatment for osteoporosis: Preclinical and early clinical studies
Abstract
Osteoporosis and several other bone disorders occur when there is an imbalance between the resorption and formation components of bone remodeling activity. Therapies available for some of these conditions modulate the activity of osteoclasts and/or osteoblasts. The recent discoveries of receptor activator of NF-kappaB ligand (RANKL), an endogenous activator of osteoclastogenenesis and osteoclast activity and its inhibitor, osteoprotegerin (OPG)...
Paper Details
Title
Inhibition of RANKL as a treatment for osteoporosis: Preclinical and early clinical studies
Published Date
Mar 1, 2006
Journal
Volume
4
Issue
1
Pages
28 - 33
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History